Julien Adam

15.2k citations

171 papers · 4.7k indexed · 2 hit papers · h-index 35

Oncology top 0.5%
Pulmonary and Respiratory Medicine top 1%
Immunology top 2%
Molecular Biology top 10%
Cancer Research top 2%

Co-authors: Benjamin Besse Vincent de Montpréville Aïcha Goubar David Planchard Fathia Mami‐Chouaib Pierre Validire Aurélie Durgeau Guillaume Meurice
Topics: Cancer Immunotherapy and Biomarkers (72 papers)Lung Cancer Treatments and Mutations (37 papers)Cancer Genomics and Diagnostics (22 papers)
Cited by: Oncology Immunology Cancer Research
Journals: Nature Communications Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: France United States Spain

In The Last Decade

Julien Adam

159 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients

2015 459 citations Julien Adam, Aïcha Goubar et al. profile →
Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis

2024 53 citations Mathieu Rouanne, Julien Adam et al. profile →

Peers

Countries citing papers authored by Julien Adam

Since Specialization

Citations

This map shows the geographic impact of Julien Adam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Adam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Adam more than expected).

Fields of papers citing papers by Julien Adam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Adam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Adam. The network helps show where Julien Adam may publish in the future.

Co-authorship network of co-authors of Julien Adam

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Adam. A scholar is included among the top collaborators of Julien Adam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Adam. Julien Adam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies 2025 ·Nature Communications ·(unknown),(unknown),Édouard Auclin,Julien Adam,Sébastien Mella,Milena Hasan,Éric Tartour,Caroline Robert,Stéphanie Corgnac,Fathia Mami‐Chouaib	0
2	The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape 2023 ·Lung Cancer ·Anne‐Marie Lefebvre,Julien Adam,Céline Nicolazzi,(unknown),(unknown),(unknown),Colette Dib,(unknown),Nils Ternès,Anne-Laure Bauchet,Brigitte Demers,Mustapha Chadjaa,Sukhvinder Sidhu,Cécile Combeau,Jean‐Charles Soria,Jean‐Yves Scoazec,Souâd Naimi,Eric Angevin,Marielle Chiron,Christophe Henry	9
3	Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort 2023 ·Biomedicines ·Soledad Iseas,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Guillermo Méndez,Marcela Carballido,Enrique Roca,(unknown),Vincent de Parades,Nabil Baba-Hamed,Julien Adam,Martı́n C. Abba,(unknown)	3
4	Harmonization of programmed death‐ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis 2022 ·Histopathology ·(unknown),Julien Adam,Laurence Lamant,Maxime Battistella,Nicolás Ortonne,B. Balme,Arnaud de la Fouchardière,Léonor Chaltiel,E. Gérard,Camille Franchet,B. Vergier	6
5	Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC 2021 ·Urologic Oncology Seminars and Original Investigations ·Myriam Kossaï,C. Radulescu,Julien Adam,(unknown),Nicolas Signolle,Mathilde Sibony,Thierry Lebrét,Yves Allory,Mathieu Rouanne	9
6	An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities 2020 ·Molecular Cancer Therapeutics ·Céline Nicolazzi,Anne Caron,Alexia Tellier,(unknown),Jan Pinkas,Gillian Payne,(unknown),S. Guérif,(unknown),Raffaele Baffa,Matteo Fassan,Julien Adam,(unknown),Véronique Blanc	23
7	Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment 2020 ·ESMO Open ·Alice Boilève,Armelle Dufresne,Ali N. Chamseddine,Elise F. Nassif,Sarah Dumont,(unknown),Julien Adam,Etienne Rouleau,Marie Karanian,Véronique Haddad,Matthieu Faron,Charles Honoré,Pierre Méeus,Axel Le Cesne,Jean‐Yves Blay,Olivier Mir	2
8	PD-L1 testing in urothelial bladder cancer: essentials of clinical practice 2020 ·World Journal of Urology ·Mathieu Rouanne,C. Radulescu,Julien Adam,Yves Allory	12
9	Lung microwave ablation – an in vivo swine tumor model experiment to evaluate ablation zones 2020 ·International Journal of Hyperthermia ·(unknown),C. Tériitéhau,Julien Adam,Jimmy Kyaw Tun,Charles Roux,Antoine Hakimé,Alexandre Delpla,Frédèric Deschamps,Thierry de Baère,Lambros Tselikas	13
10	128O PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial 2020 ·Annals of Oncology ·Thomas Bachelot,Thomas Filleron,Florence Dalenc,Ivan Bièche,(unknown),Étienne Rouleau,Alicia Tran-Dien,Julien Adam,Amélie Lusque,Marta Jimenez,(unknown),Fabrice André	11
11	ROCK 2 inhibition triggers the collective invasion of colorectal adenocarcinomas 2019 ·The EMBO Journal ·(unknown),Joël Raingeaud,(unknown),(unknown),(unknown),Joel Paulo Russomano Veiga,Laëtitia Marisa,Julien Adam,Valérie Boige,David Malka,Diane Goèré,Alan Hall,(unknown),Friedrich Prall,Maximiliano Gelli,Peggy Dartigues,Fanny Jaulin	45
12	P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative 2019 ·Journal of Thoracic Oncology ·Julien Adam,Véronique Hofman,Audrey Mansuet‐Lupo,Isabelle Rouquette,(unknown),Cécile Badoual,Hugues Bégueret,Marie‐Christine Copin,Diane Damotte,Claire Danel,Fabien Forest,S. Garcia,Laure Gibault,Frédérique Penault‐Llorca,Sylvie Lantuéjoul,Aurélie Cazes,Nolwenn Le Stang	7
13	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours 2018 ·Nature Communications ·Aurélie Durgeau,Yasemin Virk,Gwendoline Gros,(unknown),Stéphanie Corgnac,(unknown),Jérôme Salmon,Julien Adam,Vincent de Montpréville,Pierre Validire,Soldano Ferrone,Salem Chouaı̈b,Alexander Eggermont,Jean‐Charles Soria,François A. Lemonnier,Éric Tartour,Nathalie Chaput,Benjamin Besse,Fathia Mami‐Chouaib	21
14	Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica 2018 ·Tumori Journal ·Linda Mahjoubi,Franco Cecchi,Christophe Massard,Fabio Calabrò,Anas Gazzah,Rastislav Bahleda,Philippe Jamme,Maximiliano Gelli,Diane Goèré,Ludovic Lacroix,Julien Adam,Lukas C. Heukamp,Patrizia Trenta,Todd Hembrough,Jean‐Charles Soria,Cora N. Sternberg,Michel Ducreux	0
15	Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer 2018 ·Annals of Oncology ·Julien Adam,Nolwenn Le Stang,Isabelle Rouquette,Aurélie Cazes,Cécile Badoual,(unknown),(unknown),Claire Danel,Francesca Damiola,Diane Damotte,Frédérique Penault‐Llorca,Sylvie Lantuéjoul	171
16	Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy 2017 ·Cancer Research ·Laetitia Fend,Takahiro Yamazaki,(unknown),(unknown),Murielle Gantzer,(unknown),Xavier Préville,Éric Quéméneur,Oliver Kepp,Julien Adam,Aurélien Marabelle,Jonathan M. Pitt,Guido Kroemer,Laurence Zitvogel	108
17	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition 2017 ·Data Archiving and Networked Services (DANS) ·Florine A. Eggink,Inge C. van Gool,Alexandra Léary,Pamela M. Pollock,Emma J. Crosbie,Linda Mileshkin,Ekaterina S. Jordanova,Julien Adam,Luke Freeman-Mills,David N. Church,Carien L. Creutzberg,Marco de Bruyn,Hans W. Nijman,Tjalling Bosse	17
18	Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids 2017 ·European Journal of Cancer ·(unknown),Gwénaël Le Teuff,J. Guigay,Caroline Caramella,A. Berdelou,Sophie Leboulleux,Désirèe Deandreis,Julien Hadoux,Michel Ducreux,Pierre Duvillard,Julien Adam,Jean‐Yves Scoazec,Éric Baudin,David Planchard	34
19	Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization 2016 ·Cancer Research ·Lise Boussemart,Isabelle Girault,Hélène Malka-Mahieu,Christine Mateus,Émilie Routier,(unknown),Nyam Kamsu-Kom,M. Thomas,Gorana Tomasic,Sandrine Agoussi,(unknown),Mélanie Laporte,Ludovic Lacroix,Alexander M.M. Eggermont,Andréa Cavalcanti,Florent Grange,Julien Adam,Stéphan Vagner,Caroline Robert	33
20	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC 2011 ·Clinical Cancer Research ·Luc Friboulet,(unknown),Frédéric Commo,Ken A. Olaussen,Stéphan Vagner,Julien Adam,Aïcha Goubar,Nicolas Dorvault,Vladimir Lazar,Bastien Job,Benjamin Besse,Pierre Validire,Philippe Girard,Ludovic Lacroix,(unknown),(unknown),Fabrice André,Jean‐Charles Soria	54

About Julien Adam

Julien Adam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 171 papers that have together received 4.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (72 papers), Lung Cancer Treatments and Mutations (37 papers) and Cancer Genomics and Diagnostics (22 papers). The work is most often cited by research in Oncology (3.0k citations), Immunology (1.4k citations) and Cancer Research (954 citations). Julien Adam has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Benjamin Besse, Vincent de Montpréville, Aïcha Goubar, David Planchard, Fathia Mami‐Chouaib, Pierre Validire, Aurélie Durgeau, Guillaume Meurice, Axel Le Cesne and Fabrice André. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact